Starting Empagliflozin During Acute HF Hospitalization Starting Empagliflozin During Acute HF Hospitalization
Improvement of symptoms and quality of life seen in acute heart failure patients who start empagliflozin during hospitalization.ACC.org (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 28, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Early Signal of Benefit for Empagliflozin in Acute MI: EMMY Early Signal of Benefit for Empagliflozin in Acute MI: EMMY
The findings increase optimism that SGLT2 inhibitors may provide clinical benefit to the post-MI population, observers say.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 2, 2022 Category: Endocrinology Tags: Cardiology News Source Type: news
Milestone Reached for SGLT2 Inhibitor Aimed at Heart Attack Population
(MedPage Today) -- BARCELONA -- Starting patients on empagliflozin (Jardiance) in the acute phase of a large myocardial infarction (MI) resulted in improvements in surrogate markers of heart failure (HF) and heart function over the next half... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 30, 2022 Category: Cardiology Source Type: news
Early Flozin Use Tied to Improved LA Strain in ACS With Diabetes Early Flozin Use Tied to Improved LA Strain in ACS With Diabetes
Left atrial (LA) function improved with predischarge empagliflozin in a new study, adding to previous data showing better diastolic function with the SGLT2 inhibitor in ACS.First Look (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 5, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Empagliflozin Eyed for Outpatient Chronic Hyponatremia Empagliflozin Eyed for Outpatient Chronic Hyponatremia
The SGLT2 inhibitor increased sodium and reduced neurocognitive dysfunction in patients with chronic hyponatremia due to the syndrome of inappropriate antidiuresis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2022 Category: Consumer Health News Tags: Nephrology News Source Type: news
Could a Type 2 Diabetes Drug Tackle Kidney Stones? Could a Type 2 Diabetes Drug Tackle Kidney Stones?
A pooled data analysis of trials of the SGLT2 inhibitor empagliflozin in type 2 diabetes suggests it may lower the risk of kidney stones. However, this is early research.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - June 20, 2022 Category: Primary Care Tags: Nephrology News Source Type: news
Boehringer Ingelheim gets CDSCO nod for Jardiance to treat for new heart failure indication
Jardiance is the top selling drug of BI in India, used in treatment of type-2 diabetes and for the treatment of heart failure with reduced ejection fraction (HFrEF). The latest approval by CDSCO is for the treatment of heart failure with preserved ejection fraction (HFpEF). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 19, 2022 Category: Pharmaceuticals Source Type: news
Positive Topline Results for Dapagliflozin in HFpEF: DELIVER Positive Topline Results for Dapagliflozin in HFpEF: DELIVER
AstraZeneca says regulatory submissions will be forthcoming, potentially bringing a second SGLT2 inhibitor in this space, after empagliflozin.News Alerts (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - May 5, 2022 Category: Internal Medicine Tags: Cardiology News Alert Source Type: news
Empagliflozin Rapidly Improves Acute Heart Failure Symptoms Empagliflozin Rapidly Improves Acute Heart Failure Symptoms
Empagliflozin showed symptomatic benefits in patients hospitalized for acute heart failure after 2 weeks in a secondary analysis from the EMPULSE trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 14, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
ACC: Empagliflozin Offers Clinical Benefit in Heart Failure
WEDNESDAY, April 13, 2022 -- For patients hospitalized for acute heart failure, treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin produces clinical benefit, according to a study published online April 4 in Circulation... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 13, 2022 Category: Pharmaceuticals Source Type: news
Himachal Pradesh high court restrains DRL from selling BI's diabetic drug Jardiance
The drugmaker said it is reviewing legal options including filing an appeal against the court order. Dr Reddy's has launched copies of Jardiance (empagliflozin), which has valid patent in India until 2025. BI has sought restraining order on manufacture and sale of the drug. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 31, 2022 Category: Pharmaceuticals Source Type: news
Empagliflozin Scores Topline Win in EMPA-KIDNEY Trial Empagliflozin Scores Topline Win in EMPA-KIDNEY Trial
Researchers stopped the 6600-patient EMPA-KIDNEY trial sooner than expected because it positively met prespecified efficacy criteria in a trial of patients with CKD with or without diabetes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 17, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Mar 4 2022 This Week in Cardiology Mar 4 2022 This Week in Cardiology
An update to CardioMEMs post, ARBs and cancer, troponins, empagliflozin, and low-value care are the topics discussed by John Mandrola, MD, in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 4, 2022 Category: Cardiology Tags: Cardiology Commentary Source Type: news
FDA Expands Approval of Jardiance for Patients With Heart Failure
MONDAY, Feb. 28, 2022 -- Approval for Jardiance (empagliflozin) has been expanded to reduce the risk for cardiovascular death and hospitalization for heart failure in adults, the U.S. Food and Drug Administration announced Thursday.
Jardiance... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 28, 2022 Category: Pharmaceuticals Source Type: news
US FDA Approves Jardiance (empagliflozin) to Treat Adults with Heart Failure Regardless of Left Ventricular Ejection Fraction
RIDGEFIELD, Conn. and INDIANAPOLIS, Feb. 24, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death and hospitalization for heart failure in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 25, 2022 Category: Drugs & Pharmacology Source Type: news
